Search

Your search keyword '"Fuller, Douglas S."' showing total 190 results
Start Over Author "Fuller, Douglas S."
190 results on '"Fuller, Douglas S."'

2. Corrigendum to “Effectiveness and tolerability in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study” [Sleep Med. 109 (2023) 65–74 ISSN 1389–9457]

Author

Bae, Charles J., primary, Zee, Phyllis C., additional, Leary, Eileen B., additional, Fuller, Douglas S., additional, Macfadden, Wayne, additional, Candler, Shawn, additional, Steininger, Teresa L., additional, and Husain, Aatif M., additional

Published
2024
Full Text
View/download PDF

10. Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study

Author

Fuller, Douglas S., Robinson, Bruce M., Locatelli, Francesco, and Pisoni, Ronald L.

Abstract

Background:Clinicians providing dialysis care have numerous erythropoiesis-stimulating agents (ESAs) available for treating anemia. We sought to provide a contemporary description of ESA types used in hemodialysis (HD) settings in nine European countries. Methods:Our study uses Dialysis Outcomes and Practice Patterns Study phase 5 (2012–2015) data from nine European countries (Belgium, France, ­Germany, Italy, Russia, Spain, Sweden, Turkey, and the United Kingdom). A total of 164 facilities and 3,281 patients contributed cross-sectional data. ESA types captured included short-acting epoetins (e.g., epoetin alfa, beta, etc., including biosimilars), darbepoetin alfa, and continuous erythropoietin receptor agonist (CERA; methoxy polyethylene glycol-epoetin beta). Results:We observed broad variability across countries in prescription of ESA types: prescription of epoetin alfa or epoetin beta ranged from 22% (France) to 78% (Russia), darbepoetin alfa prescription ranged from 13% (Russia) to 53% (UK), and CERA prescription ranged from <3% (Sweden) to 26% (France). Prescription of different ESA types varied substantially within some European countries from 2012–2015 but not across all countries in aggregate. Number of ESA types prescribed by a facility varied from 1, 2, 3, or 4 different ESA types in 32, 40, 21, and 8% of facilities, respectively. No differences were seen in the unadjusted distributions of achieved hemoglobin values by ESA type. Conclusion:A variety of short- and long-acting ESAs are commonly used in European HD facilities to maintain hemoglobin at remarkably similar levels with each ESA type. The availability of numerous ESA options for managing anemia has allowed European providers to optimize anemia management according to the particular circumstances of each patient.

Published
2024
Full Text
View/download PDF

20. Variation in Peritoneal Dialysis–Related Peritonitis Outcomes in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS)

Author

Al Sahlawi, Muthana, primary, Zhao, Junhui, additional, McCullough, Keith, additional, Fuller, Douglas S., additional, Boudville, Neil, additional, Ito, Yasuhiko, additional, Kanjanabuch, Talerngsak, additional, Nessim, Sharon J., additional, Piraino, Beth M., additional, Pisoni, Ronald L., additional, Teitelbaum, Isaac, additional, Woodrow, Graham, additional, Kawanishi, Hideki, additional, Johnson, David W., additional, and Perl, Jeffrey, additional

Published
2022
Full Text
View/download PDF

21. International peritoneal dialysis training practices and the risk of peritonitis

Author

Cheetham, Melissa S, primary, Zhao, Junhui, additional, McCullough, Keith, additional, Fuller, Douglas S, additional, Cho, Yeoungjee, additional, Krishnasamy, Rathika, additional, Boudville, Neil, additional, Figueiredo, Ana E, additional, Ito, Yasuhiko, additional, Kanjanabuch, Talerngsak, additional, Perl, Jeffrey, additional, Piraino, Beth M, additional, Pisoni, Ronald L, additional, Szeto, Cheuk C, additional, Teitelbaum, Isaac, additional, Woodrow, Graham, additional, and Johnson, David W, additional

Published
2021
Full Text
View/download PDF

22. Burden of Kidney Disease, Health-Related Quality of Life, and Employment Among Patients Receiving Peritoneal Dialysis and In-Center Hemodialysis: Findings From the DOPPS Program

Author

Brown, Edwina A., primary, Zhao, Junhui, additional, McCullough, Keith, additional, Fuller, Douglas S., additional, Figueiredo, Ana E., additional, Bieber, Brian, additional, Finkelstein, Frederic O., additional, Shen, Jenny, additional, Kanjanabuch, Talerngsak, additional, Kawanishi, Hideki, additional, Pisoni, Ronald L., additional, Perl, Jeffrey, additional, Jassal, Vanita, additional, Fukasawa, Mizuya, additional, Wilson, Scott, additional, Cheawchanwattana, Areewan, additional, Fang, Wei, additional, and Ljungman, Susanne, additional

Published
2021
Full Text
View/download PDF

23. Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS

Author

Komaba, Hirotaka, primary, Zhao, Junhui, additional, Yamamoto, Suguru, additional, Nomura, Takanobu, additional, Fuller, Douglas S., additional, McCullough, Keith P., additional, Evenepoel, Pieter, additional, Christensson, Anders, additional, Zhao, Xinju, additional, Alrukhaimi, Mona, additional, Al‐Ali, Fadwa, additional, Young, Eric W., additional, Robinson, Bruce M., additional, and Fukagawa, Masafumi, additional

Published
2021
Full Text
View/download PDF

25. International peritoneal dialysis training practices and the risk of peritonitis.

Author

Cheetham, Melissa S, Zhao, Junhui, McCullough, Keith, Fuller, Douglas S, Cho, Yeoungjee, Krishnasamy, Rathika, Boudville, Neil, Figueiredo, Ana E, Ito, Yasuhiko, Kanjanabuch, Talerngsak, Perl, Jeffrey, Piraino, Beth M, Pisoni, Ronald L, Szeto, Cheuk C, Teitelbaum, Isaac, Woodrow, Graham, and Johnson, David W

Subjects
PERITONEAL dialysis, PERITONITIS, CONFIDENCE intervals, TREATMENT effectiveness
Abstract

Background The effects of training practices on outcomes of patients receiving peritoneal dialysis (PD) are poorly understood and there is a lack of evidence informing best training practices. This prospective cohort study aims to describe and compare international PD training practices and their association with peritonitis. Methods Adult patients on PD <3 months participating in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS) were included. Training characteristics (including duration, location, nurse affiliation, modality, training of family members, use of individual/group training and use of written/oral competency assessments) were reported at patient and facility levels. The hazard ratio (HR) for time to first peritonitis was estimated using Cox models, adjusted for selected patient and facility case-mix variables. Results A total of 1376 PD patients from 120 facilities across seven countries were included. Training was most commonly performed at the facility (81%) by facility-affiliated nurses (87%) in a 1:1 setting (79%). In the UK, being trained by both facility and third-party nurses was associated with a reduced peritonitis risk [adjusted HR 0.31 (95% confidence interval 0.15–0.62) versus facility nurses only]. However, this training practice was utilized in only 5 of 14 UK facilities. No other training characteristics were convincingly associated with peritonitis risk. Conclusions There was no evidence to support that peritonitis risk was associated with when, where, how or how long PD patients are trained. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. 893810_supp_mat - Peritoneal dialysis-associated peritonitis outcomes reported in trials and observational studies: A systematic review

Author

Muthana Al Sahlawi, Wilson, Gregory, Stallard, Belinda, Manera, Karine E, Tong, Allison, Pisoni, Ronald L, Fuller, Douglas S, Yeoungjee Cho, Johnson, David W, Piraino, Beth, Schreiber, Martin J, Boudville, Neil C, Teitelbaum, Isaac, and Perl, Jeffrey

Subjects
education, Medicine
Abstract

893810_supp_mat for Peritoneal dialysis-associated peritonitis outcomes reported in trials and observational studies: A systematic review by Muthana Al Sahlawi, Gregory Wilson, Belinda Stallard, Karine E Manera, Allison Tong, Ronald L Pisoni, Douglas S Fuller, Yeoungjee Cho, David W Johnson, Beth Piraino, Martin J Schreiber, Neil C Boudville, Isaac Teitelbaum and Jeffrey Perl in Peritoneal Dialysis International

Published
2020
Full Text
View/download PDF

31. Association of erythropoietin resistance and fibroblast growth factor 23 in dialysis patients: Results from the Japanese Dialysis Outcomes and Practice Patterns Study

Author

Usui, Tomoko, primary, Zhao, Junhui, additional, Fuller, Douglas S., additional, Hanafusa, Norio, additional, Hasegawa, Takeshi, additional, Fujino, Hiroshi, additional, Nomura, Takanobu, additional, Zee, Jarcy, additional, Young, Eric, additional, Robinson, Bruce M., additional, and Nangaku, Masaomi, additional

Published
2020
Full Text
View/download PDF

32. Optimizing Peritoneal Dialysis–Associated Peritonitis Prevention in the United States

Author

Perl, Jeffrey, primary, Fuller, Douglas S., additional, Boudville, Neil, additional, Kliger, Alan S., additional, Schaubel, Douglas E., additional, Teitelbaum, Isaac, additional, Warady, Bradley A., additional, Neu, Alicia M., additional, Patel, Priti R., additional, Piraino, Beth, additional, Schreiber, Martin, additional, and Pisoni, Ronald L., additional

Published
2020
Full Text
View/download PDF

34. Peritoneal Dialysis–Related Infection Rates and Outcomes: Results From the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS)

Author

Perl, Jeffrey, primary, Fuller, Douglas S., additional, Bieber, Brian A., additional, Boudville, Neil, additional, Kanjanabuch, Talerngsak, additional, Ito, Yasuhiko, additional, Nessim, Sharon J., additional, Piraino, Beth M., additional, Pisoni, Ronald L., additional, Robinson, Bruce M., additional, Schaubel, Douglas E., additional, Schreiber, Martin J., additional, Teitelbaum, Isaac, additional, Woodrow, Graham, additional, Zhao, Junhui, additional, and Johnson, David W., additional

Published
2020
Full Text
View/download PDF

35. Peritoneal dialysis-associated peritonitis outcomes reported in trials and observational studies: A systematic review

Author

Sahlawi, Muthana Al, primary, Wilson, Gregory, additional, Stallard, Belinda, additional, Manera, Karine E, additional, Tong, Allison, additional, Pisoni, Ronald L, additional, Fuller, Douglas S, additional, Cho, Yeoungjee, additional, Johnson, David W, additional, Piraino, Beth, additional, Schreiber, Martin J, additional, Boudville, Neil C, additional, Teitelbaum, Isaac, additional, and Perl, Jeffrey, additional

Published
2020
Full Text
View/download PDF

37. International Anemia Prevalence and Management in Peritoneal Dialysis Patients

Author

Perlman, Rachel L., primary, Zhao, Junhui, additional, Fuller, Douglas S., additional, Bieber, Brian, additional, Li, Yun, additional, Pisoni, Ronald L., additional, Robinson, Bruce M., additional, Johnson, David W., additional, Kawanishi, Hideki, additional, Davies, Simon J., additional, Schreiber, Martin J., additional, and Perl, Jeffrey, additional

Published
2019
Full Text
View/download PDF

39. Serum total indoxyl sulfate and clinical outcomes in hemodialysis patients: results from the Japan Dialysis Outcomes and Practice Patterns Study.

Author

Yamamoto, Suguru, Fuller, Douglas S, Komaba, Hirotaka, Nomura, Takanobu, Massy, Ziad A, Bieber, Brian, Robinson, Bruce, Pisoni, Ronald, and Fukagawa, Masafumi

Subjects
*TREATMENT effectiveness, *HEMODIALYSIS patients, *HEMODIALYSIS, *SULFATES
Abstract

Background Uremic toxins are associated with various chronic kidney disease-related comorbidities. Indoxyl sulfate (IS), a protein-bound uremic toxin, reacts with vasculature, accelerating atherosclerosis and/or vascular calcification in animal models. Few studies have examined the relationship of IS with clinical outcomes in a large cohort of hemodialysis (HD) patients. Methods We included 1170 HD patients from the Japan Dialysis Outcomes and Practice Patterns Study Phase 5 (2012–15). We evaluated the associations of serum total IS (tIS) levels with all-cause mortality and clinical outcomes including cardiovascular (CV)-, infectious- and malignancy-caused events using Cox regressions. Results The median (interquartile range) serum tIS level at baseline was 31.6 μg/mL (22.6–42.0). Serum tIS level was positively associated with dialysis vintage. Median follow-up was 2.8 years (range: 0.01–2.9). We observed 174 deaths (14.9%; crude rate, 0.06/year). Serum tIS level was positively associated with all-cause mortality [adjusted hazard ratio per 10 μg/mL higher, 1.16; 95% confidence interval (CI) 1.04–1.28]. Association with cause-specific death or hospitalization events, per 10 μg/mL higher serum tIS level, was 1.18 (95% CI 1.04–1.34) for infectious events, 1.08 (95% CI 0.97–1.20) for CV events and 1.02 (95% CI 0.87–1.21) for malignancy events after adjusting for covariates including several nutritional markers. Conclusions In a large cohort study of HD patients, serum tIS level was positively associated with all-cause mortality and infectious events. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

42. Association of erythropoietin resistance and fibroblast growth factor 23 in dialysis patients: Results from the Japanese Dialysis Outcomes and Practice Patterns Study.

Author

Usui, Tomoko, Zhao, Junhui, Fuller, Douglas S., Hanafusa, Norio, Hasegawa, Takeshi, Fujino, Hiroshi, Nomura, Takanobu, Zee, Jarcy, Young, Eric, Robinson, Bruce M., and Nangaku, Masaomi

Subjects
FIBROBLAST growth factors, HEMODIALYSIS patients, GENERALIZED estimating equations, ERYTHROPOIETIN, CHRONIC kidney failure
Abstract

Background: Fibroblast growth factor 23 (FGF23) plays an important role in chronic kidney disease (CKD)‐related mineral and bone disorders. High FGF23 levels are associated with increased risk of anaemia in non‐haemodialysis CKD patients. FGF23 also negatively regulates erythropoiesis in mice. We hypothesized that higher FGF23 levels are associated with increased erythropoietin hyporesponsiveness among haemodialysis patients. Methods: The study included 1044 patients from the Japanese Dialysis Outcomes and Practice Patterns Study (J‐DOPPS) phase 5 (2012‐2015). The outcome was erythropoiesis‐stimulating agent hyporesponsiveness (ESA‐hypo), defined as mean Hgb <10 g/dL and standardized mean ESA dose >6000 u/week over 4 months following FGF23 measurement. The association between ESA‐hypo and FGF23 was estimated using multivariable‐adjusted logistic generalized estimating equation regression models. Results: Patients with higher levels of FGF23 were younger and had higher levels of serum albumin, creatinine, albumin‐corrected calcium, phosphorus, PTH, 25(OH)‐vitamin D, and had higher percentages of intravenous (IV) iron, IV vitamin D and cinacalcet use. ESA‐hypo was present in 144 patients (13.8%). Compared with the third quintile of FGF23 levels, the odds ratio (95% CI) of ESA‐hypo was 2.14 (0.99, 4.62) and 1.74 (0.74, 4.11) for the first and fifth quintiles, respectively. Conclusion: The lowest and highest levels of FGF23 were associated with higher odds of ESA‐hypo in patients on maintenance haemodialysis, although the associations were not statistically significant. The relationship between FGF23 and anaemia, and particularly the increased risks of ESA‐hypo at low FGF23 levels which might be the result of energy saving, must be confirmed in larger clinical studies. SUMMARY AT A GLANCE: The study included 1044 patients in Japan from J‐DOPPS and found that the lowest and highest levels of serum FGF‐23 were associated with increased odds of ESA‐hyporesponsiveness in patients on maintenance haemodialysis, though this did not reach statistical significance. Further study is needed to address the relationship between circulating FGF‐23 and anaemia in dialysis patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

43. Combinations of mineral and bone disorder markers and risk of death and hospitalizations in the international Dialysis Outcomes and Practice Patterns Study.

Author

Fuller, Douglas S, Dluzniewski, Paul J, Cooper, Kerry, Bradbury, Brian D, Robinson, Bruce M, and Tentori, Francesca

Subjects
*HEMODIALYSIS patients, *BONES, *PARATHYROIDECTOMY, *HOSPITAL care, *PARATHYROID hormone
Abstract

Background Prior studies have developed a chronic kidney disease–mineral and bone disorder (CKD-MBD) composite score based on combinations of calcium (Ca), phosphorus (P) and parathyroid hormone (PTH) that have been shown to be associated with an increased risk of clinical outcomes in the USA. We examined this association in a contemporary, international cohort of hemodialysis patients. Methods We studied 19 313 patients surviving ≥12 months in the Dialysis Outcomes and Practice Patterns Study Phases 3–5 (2005–15) from Europe, Canada and the USA. The CKD-MBD composite score was defined as the number of markers above target levels (P, 3.5–5.5 mg/dL; Ca, 8.4–10.2 mg/dL; PTH, 150–600 pg/mL). Using Cox models, we estimated hazard ratios (HRs) for death and a composite event (death or hospitalization), contrasting MBD 2/3 (2–3 parameters above target) with MBD 0 (all in target), adjusted for a disease risk score (DRS). Results MBD 2/3 above target was observed in 10–14% of patients across regions and was associated with greater DRS-adjusted mortality {HR 1.41 [95% confidence interval (CI) 1.10–1.82]} and composite events [HR 1.23 (95% CI 1.10–1.38)] in the USA compared with MBD 0; the mortality association was stronger for patients ≥ 65 years of age [HR 1.82 (95% CI 1.28–2.58)] compared with patients <65 years of age [HR 1.11 (95% CI 0.80–1.55)]. HRs observed in Canada and Europe were generally consistent but weaker. Estimates for MBD 2/3 outside target (above or below) were slightly lower in all regions. Conclusions Simultaneous consideration of Ca, P and PTH may help in identifying patients on dialysis with a higher risk of major clinical outcomes related to CKD-MBD. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results